Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran

References

• Gund BM, Jagtap PN, Ingale VB, Patil RY. Stroke: A brain attack IOSR Journal of Pharmacy 2013;3:1-23
   Google Scholar
• Cotrina ML, Lou N, Tome-Garcia J, Goldman J, Nedergaard M. Direct comparison of microglial dynamics and inflammatory profile in photothrombotic and arterial occlusion evoked stroke Neuroscience 2017;343:483-94
   PubMed Web of Science ®Google Scholar
• Miller EL, Murray L, Richards L, Zorowitz RD, Bakas T, Clark P, Billinger SA. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient. Stroke. 2010;41:2402–48.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. The Lancet. 2014;383:245–55.
   PubMed Web of Science ®Google Scholar
• Marier J. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR. Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2013;44:870–947.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. New England Journal of Medicine. 2008;359:1317–29.
   PubMed Web of Science ®Google Scholar
• Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. The Cochrane Library. 2014.
   Google Scholar
• Wardlaw JM, Murray V, Berge E, Del Zoppo G, Sandercock P, Lindley RL, Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. The Lancet. 2012;379:2364–72.
   PubMed Web of Science ®Google Scholar
• Jung KT, Shin DW, Lee KJ, Oh M. Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. Journal of Clinical Neurology. 2010;6:117–26.
   PubMed Web of Science ®Google Scholar
• Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4.5-hour time window for acute ischemic stroke. Stroke 2011;42:2257-62
   PubMed Web of Science ®Google Scholar
• Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B. Cost-Effectiveness of Thrombolysis Within 4.5 Hours of Acute Ischemic Stroke. Stroke. 2013;44:2269–74.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Annals of emergency medicine. 2013;61:46–55.
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke. Stroke. 2014;45:3032–9.
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, Liu G, Liu L, Wang C, Wang Y, Wang Y. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PloS one. 2014;9:e110525.
   PubMed Web of Science ®Google Scholar
• Araújo DV, Teich V, Passos RB, Martins SC. Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke. Arquivos brasileiros de cardiologia. 2010;95:12–20.
   PubMed Web of Science ®Google Scholar
• Fox-Rushby J, Cairns J. Economic evaluation. McGraw-Hill Education, London (UK); 2005.
   Google Scholar
• Edejer TT, editor. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization, Geneva; 2003.
   Google Scholar
• Ministry of health and medical education, Acute brain stroke treatment manage-ment services certificate. Scientific committee of management of acute stroke treatment, Tehran, 2015.
   Google Scholar
• Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014:STR-0000000000000024.
   Google Scholar
• Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50:883–90.
   PubMed Web of Science ®Google Scholar
• Davis S, ScHARR XX, Holmes M, ScHARR XX, Simpson E, Sutton A. Alteplase for the treatment of acute ischaemic stroke (review of technology appraisal 122).
   Google Scholar
• Herndon RM. Handbook of neurologic rating scales. Demos medical publishing; 1997.
   Google Scholar
• Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015;46:2591–8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Life tables by country Iran (Islamic Republic of). WHO, Geneva; 2015. Available at: http://apps.who.int/gho/data/?theme¼main&vid¼60760
   Google Scholar
• Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Thomas B, Wardlaw J. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health technology assessment (Winchester, England). 2002.
   Google Scholar
• Wardlaw JM, Lewis SC, Dennis MS, Counsell C, McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke?. Stroke. 1998;29:1315–9.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). The Lancet. 1998;352:1245–51.
   PubMed Web of Science ®Google Scholar
• Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P. Is the EuroQol a valid measure of health-related quality of life after stroke?. Stroke. 1997;28:1876–82.
   PubMed Web of Science ®Google Scholar
• Mahboub-Ahari A. Stated time preferences for health: a sys-tematic review and meta analysis of private and social discount rates. Tehran: Tehran University of Medical Science; 2014. p. 181–6
   Google Scholar
• Iran, Central bank of Islamic Republic of Iran. Exchange rate. 2016. Available at: http://www.cbi.ir/ExRates/rates_fa.aspx
   Google Scholar